Healthcare
Health
Medical
Fresenius Medical Care
$38.089876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$38.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.36 (0.95%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell FMS and other stocks, options, ETFs, and crypto commission-free!
About
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. Read More It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
CEO
Employees
112,658
Headquarters
Bad Homburg, Hessen
Founded
2006
Market Cap
23.25B
Price-Earnings Ratio
10.12
Dividend Yield
1.40
Average Volume
243.47K
High Today
$38.18
Low Today
$37.89
Open Price
$37.93
Volume
32.77K
52 Week High
$53.40
52 Week Low
$30.99
Collections
Healthcare
Health
Medical
Europe (Non-UK)
Europe
News
ReutersMay 16
Shareholders reproach Germany's Fresenius Medical Care after foreign bribery case
* Fresenius Medical Care AGM held on Thursday * Executive board gets approval rating of 56.81 pct * ISS recommends no confidence vote on U.S. bribery settlement BERLIN, May 16 (Reuters) - Fresenius Medical Care on Thursday became the latest German company to face a reproach from investors, with only a narrow majority of shareholders giving its top management and supervisory board their vote of approval. At the dialysis clinic operator’s annual general meeting, 56.81 percent of shareholders voted in favo...
Seeking AlphaMay 16
Fresenius Medical Care goes ex-dividend tomorrow
Fresenius Medical Care (NYSE:FMS) declares $0.452/share annual dividend. Payable May 31; for shareholders of record May 20; ex-div May 17. See FMS Dividend Scorecard, Yield Chart, & Dividend Growth....
PR NewswireMay 7
CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance
MONMOUTH JUNCTION, N.J., May 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending March 31, 2019. First Quarter 2019 Financial Results: Total revenue for Q1 2019 was $5.2 million , including both product sales and grant income, compared to $4.9 million...
Price Paid on Robinhood
5% Lower
Right Now
52 Week Low
$30.99
Average Price Paid
$40.05
52 Week High
$53.40
Earnings
$0.48
$0.76
$1.03
$1.31
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Available Jul 30, Pre-Market